- Home
- MGTX vs ARVN Comparison
MGTX vs ARVN Comparison
Compare MGTX & ARVN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | MGTX | ARVN |
|---|---|---|
| Founded | 2015 | 2015 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Biological Products (No Diagnostic Substances) | Biotechnology: Pharmaceutical Preparations |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 610.1M | 658.2M |
| IPO Year | 2018 | 2018 |
Fundamental Metrics
Financial Performance| Metric | MGTX | ARVN |
|---|---|---|
| Price | $9.19 | $9.97 |
| Analyst Decision | Strong Buy | Buy |
| Analyst Count | 7 | 19 |
| Target Price | ★ $24.57 | $15.05 |
| AVG Volume (30 Days) | ★ 1.1M | 692.7K |
| Earning Date | 05-12-2026 | 05-04-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | 33.02 | ★ 58.84 |
| EPS | N/A | ★ N/A |
| Revenue | $81,391,000.00 | ★ $262,600,000.00 |
| Revenue This Year | $141.38 | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | ★ 144.57 | N/A |
| 52 Week Low | $5.02 | $5.90 |
| 52 Week High | $11.85 | $14.22 |
Technical Indicators
Market Signals| Indicator | MGTX | ARVN |
|---|---|---|
| Relative Strength Index (RSI) | 50.13 | 34.92 |
| Support Level | $7.21 | $9.96 |
| Resistance Level | $9.65 | $10.18 |
| Average True Range (ATR) | 0.76 | 0.40 |
| MACD | -0.19 | -0.04 |
| Stochastic Oscillator | 14.19 | 14.38 |
Price Performance
Historical ComparisonAbout MGTX MeiraGTx Holdings plc
MeiraGTx Holdings PLC is a clinical-stage gene therapy company. It focuses on the eye, salivary gland, and central nervous system disorders. The company's pipeline products include AAV-CNGB3, AAV-CNGA3 and AAV-RPGR, and others. Geographically, it operates in the United States, the United Kingdom, and European Union.
About ARVN Arvinas Inc.
Arvinas Inc is a clinical-stage biotechnology company focused on improving the lives of patients suffering from debilitating and life-threatening diseases through the discovery, development, and commercialization of therapies that degrade disease-causing proteins. The company is using its PROteolysis TArgeting Chimera, a protein degradation platform, to develop therapeutics designed to harness the body's own natural protein disposal system to selectively and efficiently degrade and remove disease-causing proteins. Its clinical development program includes various product candidates such as ARV-102, ARV-806, ARV-393, ARV-027, and vepdegestrant, in their different stages of development, being developed to target certain harmful proteins causing oncology and neurology-related diseases.